Masitinib in oncology

MASITINIB

AB Science is developing masitinib in various indications in oncology, either as a single agent, or in combination with chemotherapies.


Indication Study Current status
GIST in first-line treatment
  • Indication : treatment of patients with gastro-intestinal stromal tumour in first line treatment
  • Objective : to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg
  • Design : Prospective, multicenter, randomised, open-label, active-controlled
Phase 3
On-going
GIST in second-line treatment
  • Indication : treatment of patients with gastro-intestinal stromal tumour after progression with imatinib
  • Objective : to compare efficacy and safety of masitinib to sunitinib
  • Design : Prospective, multicenter, randomised, open-label, active-controlled, 2-parallel group
Phase 3
On-going
Metastatic melanoma with JM mutation of c-KIT
  • Indication : treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit
  • Objective : to compare efficacy and safety of masitinib to dacarbazine
  • Design : Prospective, multicenter, randomised, open-label, active-controlled, 2-parallel group
Phase 3
On-going
Metastatic pancreatic cancer
  • Indication : treatment of patients with non resectable locally advanced or metastatic pancreatic cancer
  • Objective : to compare efficacy and safety of masitinib in combination with gemcitabine and folfiri to placebo in combination with gemcitabine and folfiri
  • Design : Prospective, multicenter, double-randomised, double-blind, 2-parallel group
Phase 3
On-going
Relapsed metastatic colorectal cancer
  • Indication : treatment of patients with metastatic colorectal cancer in third or fourth line
  • Objective : to compare efficacy and safety of masitinib in combinaison with folfiri to masitinib alone to Best Supportive Care
  • Design : Prospective, multicenter, randomised, open-lable, active-controlled, three parallel groups
Phase 3
On-going
Metastatic Castrate Resistant Prostate Cancer in first line
  • Indication : treatment of patients with metastatic Castrate Resistant Prostate Cancer in first line
  • Objective : to compare efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel
  • Design : Prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups
Phase 3
On-going
Relapsed metastatic ovarian cancer
  • Indication : treatment of patients with advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
  • Objective : to compare efficacy and safety of masitinib efficacy and safety of masitinib in combination to gemcitabine versus gemcitabine alone
  • Design : Prospective, multicentre, open-label, centrally allocated, active-controlled
Phase 3
On-going
Relapsed peripheral T-cell lymphoma
  • Indication : treatment of patients with relapsed or refractory peripheral T-cell lymphoma
  • Objective : to compare efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination of masitinib, gemcitabine and dexamethasone
  • Design : Multicenter, randomised, open-label, 3-parallel group
Phase 3
On-going